Mauna Kea Technologies Announces Q2 and 1H 2022 Revenues

Mauna Kea Technologies Announces Q2 and 1H 2022 Revenues

Stable YTD Revenue while Strategic Realignment Implemented 35% 1H U.S. Sales Growth offset by Declines in Asia Recently announced Tasly Pharmaceuticals JV and licensing agreements expected to produce new revenue stream Mauna Kea Technologies today announced its...